Sonoma Biotherapeutics Reports Encouraging Early Results from Phase 1 Trial in Treatment-Resistant Rheumatoid Arthritis

Sonoma Biotherapeutics announced encouraging early results from its Phase 1 trial of SBT-77-7101 for treatment-resistant rheumatoid arthritis. The therapy showed strong safety and early signs of effectiveness, with most patients experiencing significant reductions in joint inflammation. These findings suggest potential for a new, targeted Treg cell therapy for autoimmune diseases without the need for chemotherapy.